For the quarter ending September 30, Inovio reported a loss of $0.89 per share, beating analyst estimates of a $1.15 loss per share, according to Stocktwits data.

Inovio’s revenue came in at $0.11 million in line with analyst estimates.| Image Source: Pixabay

Rimin Dutt·Stocktwits

Updated Jul 02, 2025 | 8:31 PM GMT-04

Add us on

Shares of Inovio Pharmaceuticals Inc. ($INO) dipped more than 10% during mid-day trading on Friday after the company’s third-quarter earnings beat analyst estimates, but retail sentiment on Stocktwits remained upbeat.

For the quarter ended September 30, Inovio posted net loss of $25.2 million, or $0.89 per basic and diluted share, compared to net loss of $33.9 million, or $1.52 per basic and diluted share in the same period last year.

For the quarter ending September 30, Inovio reported a loss of $0.89 per share, beating analyst estimates of a $1.15 loss per share, according to Stocktwits data.

Inovio’s revenue came in at $0.11 million in line with analyst estimates.

Retail sentiment on the stock improved to ‘extremely bullish’ (92/100) from ‘bullish’ (64/100) a day ago. Message volume remained at ‘extremely high’ levels.

Screenshot 2024-11-16 at 12.02.45 AM.png — INO sentiment and message volumes on Stocktwits on Nov 15 as of 1:32 pm

In fresh guidance, the company said it estimates its cash runway to extend into the third quarter of 2025. This projection includes an operational net cash burn estimate of about $24 million for the fourth quarter of 2024.

Plymouth Meeting, Pa.-based company is focused on developing DNA medicines to help treat HPV-related diseases, cancer, and other infections. Its lead product candidate, INO-3107,has shown to prompt an immune response that helps reduce the need for surgery in recent trials.

“We continue to be focused on advancing INO-3107 and delivering a non-surgical option to RRP patients,” Jacqueline Shea, Inovio's President and CEO said in a statement.

According to the third-quater report, Inovio’s cash position has shrunk compared to the end of last year. As of September 30, cash and short-term investments were $84.8 million compared to $145.3 million as of December 31, 2023.

The company’s R&D expenses rose to $18.7 million compared to $15.5 million for the same period in 2023.

Meanwhile, its G&A expenses were slightly down, attributable to a decrease in employee compensation, including non-cash employee and consultant stock-based compensation, among other factors.

Many Stocktwits users were bullish:

Inovio Pharmaceuticals stock is down 36.3% year-to-date.

For updates and corrections, please email newsroom@stocktwits.com